EULAR RA Recommendations: Start Methotrexate, Steroids First EULAR RA Recommendations: Start Methotrexate, Steroids First
Contrary to ACR guidance, EULAR recommends starting methotrexate and glucocorticoids but dose reduction and discontinuation are emphasized.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - June 6, 2022 Category: Rheumatology Tags: Rheumatology News Source Type: news
FDA approves RIABNI ™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for adults with moderate to severe rheumatoid arthritis
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. (Source: World Pharma News)
Source: World Pharma News - June 6, 2022 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Can Methotrexate Treat Arthritis Before It Becomes Arthritis?
(MedPage Today) -- COPENHAGEN -- Methotrexate helped high-risk individuals with aching and inflamed joints, but who didn't yet have overt rheumatoid arthritis (RA), avoid that diagnosis for close to 2 years in a randomized trial, a researcher... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - June 2, 2022 Category: Rheumatology Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Ex-Hospital Porter a Neglected Giant of Cancer Research Ex-Hospital Porter a Neglected Giant of Cancer Research
Dr Yellapragada SubbaRow never received rightful recognition for developing methotrexate, a powerful, inexpensive therapy for leukemia and other diseases, and additional scientific achievements.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Reduced-Frequency Methotrexate Monitoring Causes No Harm Reduced-Frequency Methotrexate Monitoring Causes No Harm
Laboratory blood test results were similar despite moving from once every month to about once every 3 months or about once every 5 months during the pandemic.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 12, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Investor Update - April 4, 2022 Category: Pharmaceuticals Source Type: news
U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Media News - April 4, 2022 Category: Pharmaceuticals Source Type: news
Toward More Uniform Methotrexate Dosing in Psoriasis
(MedPage Today) -- With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 30, 2022 Category: Dermatology Source Type: news
Trial Gives New Guidance for Choosing Initial PsA Treatment Trial Gives New Guidance for Choosing Initial PsA Treatment
Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than escalating the methotrexate dose alone.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 21, 2022 Category: Internal Medicine Tags: Rheumatology News Source Type: news
Methotrexate Plus Leflunomide Proves Effective for PsA Methotrexate Plus Leflunomide Proves Effective for PsA
The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did come with an increase in side effects.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 8, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
Suspend Methotrexate for RA Patients Getting COVID Vax?
(MedPage Today) -- A COVID-19 vaccine's immunogenicity was increased in rheumatoid arthritis patients when they stopped methotrexate temporarily after each dose in a randomized trial, but this benefit came with a cost.
Nearly 80% of patients for... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - February 23, 2022 Category: Rheumatology Source Type: news
Methotrexate-Related AEs Profiled in Early Rheumatoid Arthritis
WEDNESDAY, Feb. 9, 2022 -- Adverse events are common among patients during the first year of treatment with methotrexate for early rheumatoid arthritis, according to a study published online Jan. 25 in Rheumatology.
Ahmad A. Sherbini, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 9, 2022 Category: Pharmaceuticals Source Type: news
Machine Learning IDs Predictors of Treatment Response in RA
MONDAY, Jan. 3, 2022 -- Machine learning (ML) integrating clinical and genomic data can be used to predict methotrexate treatment response in early rheumatoid arthritis (RA), according to a study published online Dec. 13 in Arthritis Care&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2022 Category: Pharmaceuticals Source Type: news
Mayo Clinic researchers use AI, biomarkers to personalize rheumatoid arthritis treatment
ROCHESTER, Minn. ― Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients will respond to treatments, and to personalize care. Findings were published in Arthriti s Care& Research. The study focused on predicting the response to methotrexate, one of the most common rheumatoid arthritis medications. Applying patient data that included genomic, clinical and demographic… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 17, 2021 Category: Databases & Libraries Source Type: news
